SGCB and sarcopenia: The present study demonstrated for the first time that treatment with an sGC activator vericiguat prevented doxorubicin-mediated cardiovascular diseases and sarcopenia in vitro models of cancer-therapeutics-related cardiac dysfunction (CTRD).